Evidence map›Paper›PMID 30587953›Full record

ReviewInternational journal of chronic obstructive pulmonary disease2018

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.

Lowie Vanfleteren, Leonardo M Fabbri, Alberto Papi, Stefano Petruzzelli, Bartolome Celli

3 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01911364 phase3completednot on this map

A 52-wk Randomized Double Blind Parallel Trial: Combination of Beclometasone+Formoterol+Glycopyrrolate vs Tiotropium and vs Combination of Beclometasone+Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease

TypeinterventionalSponsorChiesi Farmaceutici S.p.A.Ran2014 to 2016Enrolled3,686ConditionsChronic Obstructive Pulmonary DiseaseArmsBDP/FF/GB, Tiotropium, BDP/FF + Tiotropium
NCT01917331 phase3completednot on this map

A Phase 3 Randomised Double Blind Randomised Parallel Multinational Trial Comparing a Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate to Foster® in Patients With Chronic Obstructive Pulmonary Disease

TypeinterventionalSponsorChiesi Farmaceutici S.p.A.Ran2014 to 2016Enrolled1,368ConditionsChronic Obstructive Pulmonary Disease (COPD)ArmsBeclometasone/Formoterol/Glycopyrrolate, Beclometasone/Formoterol
NCT02579850 phase3completednot on this map

52-week, Double Blind, Randomized, 2 Active Parallel Arms Study of Fixed Combination CHF 5993 Administered vs Ultibro® in COPD Patients

TypeinterventionalSponsorChiesi Farmaceutici S.p.A.Ran2015 to 2017Enrolled1,532ConditionsChronic Obstructive Pulmonary Disease (COPD)ArmsCHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo, Central spirometry, COPD assessment test, Local laboratory Assessments
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. DT-0111: a novel P2X3 receptor antagonist.Purinergic signalling · 2023
    Article
  12. Article
  13. Review
  14. Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study.International journal of chronic obstructive pulmonary disease · 2023
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Lowie VanfleterenCOPD Center, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden, lowie.vanfleteren@vgregion.se.
Leonardo M FabbriCOPD Center, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden, lowie.vanfleteren@vgregion.se.
Alberto PapiSection of Cardiorespiratory and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Stefano PetruzzelliGlobal Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Bartolome CelliDivision of Pulmonary and Critical Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
University of Ferrara · ITBrigham and Women's Hospital · USChiesi (Italy) · ITMaastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, two "fixed triple" single-inhaler combinations of an inhaled corticosteroid (ICS), a long-acting β

Indexed as

Administration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsEvidence-Based MedicineHumansLungMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveRecovery of FunctionRisk FactorsSeverity of Illness IndexTreatment OutcomeAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsMuscarinic Antagonistsadrenergic β2 receptor agonistschronic obstructiveexacerbationsglucocorticoidsmuscarinic antagonistspulmonary diseasereviewsafety

Identifiers

PMID30587953
PMCPMC6296179
OpenAlexW2904462760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.